Theravance Biopharma TBPH Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -3.4%+69.6pp | -72.9%+24.7pp | -97.6%+81.5pp | -179.1%+287pp | |
| Net margin | 98.5%+186pp | -87.6%+8.5pp | -96.1%-1,795pp | 1,698.5%+2,059pp | |
| EBITDA margin | -1.8%+68.4pp | -70.3%+23.8pp | -94.1%+77.8pp | -171.9%+286pp | |
| Free cash flow margin | 221.9%+240pp | -18.4%+32.9pp | -51.3%+314pp | -365.3%+16.7pp | |
| Returns | |||||
| Return on equity | 44.8%+73.9pp | -29%-12.2pp | -16.9%— | —— | |
| Return on assets | 25.2%+40.5pp | -15.3%-4.2pp | -11.2%-189pp | 177.6%+225pp | |
| Return on invested capital | -1.6%+21.2pp | -22.9%+3.9pp | -26.8%— | —— | |
| Efficiency | |||||
| Asset turnover | 0.3×+0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | |||||
| Current ratio | 10.9×+5.9× | 5×-0.4× | 5.4×-6.9× | 12.3×+8.0× | |
| Quick ratio | 10.9×+5.9× | 5×-0.4× | 5.4×-6.9× | 12.3×+8.0× | |
| Cash ratio | 4.4×+3.2× | 1.2×-0.4× | 1.6×-8.8× | 10.4×+8.8× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.3×+0.1× | 0.2×+0.1× | 0.1×— | |
| Debt-to-assets | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Interest coverage | -1.5×+17.0× | -18.4×+5.4× | -23.8×-9.4× | -14.4×-5.2× | |
| Per Share | |||||
| Book value per share | $5.76+60.3% | $3.59-6.7% | $3.85-35.8% | $6.00+223% | |
| Valuation | |||||
| Market capitalization | $890.32M+68.7% | $462.73M-16.7% | $555.42M-26.5% | $756.17M-9.1% | |
| Enterprise value | $642.72M+38.3% | $474.75M-16.0% | $565.04M+10.8% | $510.16M-35.8% | |
| Price / earnings | 7.8×— | —— | —— | 0.9×— | |
| Price / sales | 8.1×0.0× | 7.2×-2.5× | 9.7×-5.1× | 14.7×-0.3× | |
| Price / book | 3.1×-0.1× | 2.6×0.0× | 2.6×+0.9× | 1.7×— | |
| EV / sales | 5.9×-1.3× | 7.4×-2.5× | 9.8×-0.1× | 9.9×-4.4× | |
| Free cash flow yield | 25.2%+27.7pp | -2.6%+2.7pp | -5.3%+19.5pp | -24.8%+0.6pp | |
| Earnings yield | 12.8%+23.8pp | -12.2%-2.3pp | -9.9%-125pp | 115.3%+139pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Theravance Biopharma's profit margins?
- Theravance Biopharma (TBPH) runs a 60.8% gross margin and a 1.2% operating margin, with a 104.3% net margin.
- Where do Theravance Biopharma's ratios come from?
- Every ratio is computed from Theravance Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
